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Interleukin-6 (IL-6) plays a paradoxical role in inflam-
mation and metabolism. The pro-inflammatory ef-
fects of IL-6 are mediated via IL-6 ‘‘trans-signaling,’’
a process where the soluble form of the IL-6 receptor
(sIL-6R) binds IL-6 and activates signaling in inflam-
matory cells that express the gp130 but not the IL-6
receptor. Here we show that trans-signaling recruits
macrophages into adipose tissue (ATM). Moreover,
blocking trans-signaling with soluble gp130Fc
protein prevents high-fat diet (HFD)-induced ATM
accumulation, but does not improve insulin action.
Importantly, however, blockade of IL-6 trans-
signaling, unlike complete ablation of IL-6 signaling,
does not exacerbate obesity-induced weight gain,
liver steatosis, or insulin resistance. Our data identify
the sIL-6R as a critical chemotactic signal for ATM
recruitment and suggest that selectively blocking
IL-6 trans-signaling may be a more favorable treat-
ment option for inflammatory diseases, compared
with current treatments that completely block the
action of IL-6 and negatively impact upon metabolic
homeostasis.
INTRODUCTION
The cytokine interleukin 6 (IL-6) is a therapeutic target for many
pro-inflammatory diseases, and tocilizumab, a humanized IL-6
receptor inhibiting monoclonal antibody, is approved for clinical
use in >100 countries for the treatment of rheumatoid arthritis
(RA) (Nishimoto et al., 2005) and other pro-inflammatory dis-
eases (Febbraio et al., 2010). Since the seminal discovery 20Ceyears ago by Hotamisligil and colleagues that tumor necrosis
factor alpha (TNF-a) was highly expressed within adipose tissue
in several rodent models of obesity (Hotamisligil et al., 1993),
inflammation has become a major mechanism linking obesity
to type 2 diabetes (T2D). Given that IL-6 is pro-inflammatory, it
is widely accepted that, like TNF-a, IL-6 negatively impacts on
obesity-induced insulin resistance (Lazar, 2005). In some cir-
cumstances, administration of an IL-6-neutralizing antibody to
genetic mouse models of obesity improves metabolic homeo-
stasis (Cai et al., 2005; Sabio et al., 2008). However, evidence
gathered over the last decade has challenged the concept that
IL-6 has a negative impact on metabolic homeostasis. IL-6-
deficient (IL-6/) mice develop mature onset obesity (Wallenius
et al., 2002), glucose intolerance, insulin resistance, and
increased liver inflammation in response to a high-fat diet
(HFD) (Matthews et al., 2010). In addition, complete blockade
of IL-6 signaling in hepatocytes (Wunderlich et al., 2010) or mac-
rophages (Mauer et al., 2014), by tissue-specific deletion of the
IL-6 receptor (IL-6R), produces a similar negative metabolic
phenotype. It is important to note that IL-6 activates the fuel-
sensing kinase AMPK, a known insulin sensitizer, and infusion
of recombinant IL-6 into healthy humans improves insulin action
during a hyperinsulinemic-euglycemic clamp (Carey et al., 2006).
Consistent with these results, tocilizumab, while very effective in
treating RA, results in weight gain and hyperlipidemia (Nishimoto
et al., 2005).
The controversy regarding the role of IL-6 in metabolic
homeostasis may be due to its complex signaling biology. The
pro-inflammatory effects of IL-6 signaling appear to be mediated
via so called IL-6 ‘‘trans-signaling’’ (Kraakman et al., 2013; Rose-
John et al., 2007). IL-6 trans-signaling is a process by which the
IL-6R can be cleaved by the metalloproteinases ADAM10
(Matthews et al., 2003) and/or ADAM17 (Chalaris et al., 2010), re-
sulting in a soluble form of the IL-6R (sIL-6R). IL-6 can bind to
the sIL-6R, giving this circulating ligand/receptor complex the ca-
pacity to signal in cells that express the gp130, but not IL-6R, onll Metabolism 21, 403–416, March 3, 2015 ª2015 Elsevier Inc. 403
their plasma membrane. Importantly, specifically blocking IL-6
trans-signaling by genetic overexpression of or pharmacological
treatment with soluble glycoprotein 130 protein (sgp130Fc) can
prevent inflammation in both an air-pouch model of local inflam-
mation (Rabe et al., 2008) and in atherosclerosis (Schuett et al.,
2012). Notably, sgp130Fc does not block the activity of IL-6-
mediated signaling via the membrane-bound IL-6R (Jostock
et al., 2001). These findings led us to hypothesize that blocking
IL-6 trans-signaling is a therapeutic strategy for preventing adi-
pose tissuemacrophage (ATM) accumulation and subsequent in-
sulin resistance in obesity, since ablation of macrophages using
genetic (Patsouris et al., 2008) or pharmacological (Feng et al.,
2011) approaches leads to a reduction in local and systemic
markers of inflammation and a concomitant improvement in
insulin sensitivity in mice fed a HFD. Such a scenario could repre-
sent a major clinical breakthrough in the treatment of T2D, since
sgp130Fc has recently entered human clinical trials for the
treatment of auto-immune diseases. Here, we show that IL-6
trans-signaling is a major chemotactic signal in ATM recruitment.
Moreover, blocking IL-6 trans-signaling with sgp130Fc can pre-
vent HFD-induced ATM recruitment. While this alone is insuffi-
cient to improve HFD-induced insulin resistance, blocking IL-6
trans-signaling does not result in exacerbated weight gain, liver
steatosis, or insulin resistance, as we previously observed with
complete IL-6 blockade (Matthews et al., 2010).
RESULTS
The sIL-6R Is a Major Chemotactic Cytokine that
Correlates with Type 2 Diabetes
Patients with T2D have elevated plasma sIL-6R (Kado et al.,
1999), but the significance of this observation is unclear. To
determinewhether the sIL-6R plays a role in inflammation, insulin
resistance, or T2D, we first studied three age-matched cohorts
of patients: a lean group (Lean), obese patients with impaired
glucose tolerance (Obese, IGT), and obese patients with type 2
diabetes (Obese, T2D). The patients’ characteristics, as well as
confirmation of the categorization of Obese, IGT versus Obese,
T2D status in the patients, are described in detail in Table S1.
We obtained plasma and abdominal subcutaneous white adi-
pose tissue (WAT) biopsy samples from these patients and
analyzed them for markers of inflammation and components of
IL-6 signaling. The mRNA expression of the macrophage marker
CD68was higher in theWAT of Obese, T2D compared with Lean
(Figure 1A). Both the mRNA expression of ADAM17 in WAT (Fig-
ure 1A) and plasma sIL-6R concentration (Figure 1B) were higher
in both obese groups compared with Lean, but the plasma
concentration of sgp130 did not differ among groups (Figure 1B).
To ascertain whether these observations were related, we per-
formed correlation analyses. As expected, themRNA expression
of WAT CD68 positively correlated with both HOMA-IR (Fig-
ure 1C) and HbA1c (Figure 1D), indicating that ATMs are, indeed,
a marker of insulin resistance and T2D. The concentration of sIL-
6R in plasma also positively correlated with HOMA-IR, HbA1c,
and body mass (Figures 1E–1G), indicating that the sIL-6R is
also a disease marker. We further examined whether the sIL-
6R was related to themRNA expression ofCD68 in WAT of these
patients and, importantly, observed a significant correlation
between these twomeasures (Figure 1H). These data suggested404 Cell Metabolism 21, 403–416, March 3, 2015 ª2015 Elsevier Inc.that the sIL-6R is amajor chemotactic signal for ATM recruitment
in human obesity. Given the tight association between ATM
accumulation and sIL-6R in both humans, we next tested if
IL-6 trans-signaling could directly induce bone marrow-derived
macrophage chemotaxis in a cell migration assay system. To
mimic trans-signaling, we used Hyper-IL-6, a fusion protein
that mimics IL-6 trans-signaling (Fischer et al., 1997). As ex-
pected, monocyte chemoattractant protein-1 (MCP-1) (positive
control) induced marked macrophage chemotaxis in a dose-
dependent manner. Importantly, Hyper-IL-6 induced macro-
phage chemotaxis with efficacy similar to that of MCP-1,
providing clear evidence that IL-6 trans-signaling is a potent
chemotactic signal (Figure 1I). Moreover, Hyper-IL-6-induced
macrophage recruitment was completely blocked in the pres-
ence of sgp130Fc (Figure 1I). Sgp130Fc did not affect MCP-1-
induced chemotaxis, suggesting that the anti-chemotactic ef-
fects of sgp130Fc selectively block the chemotactic signaling
mediated by the sIL-6R (Figure 1I). Taken together, these results
demonstrate that IL-6 trans-signaling can induce macrophage
and that ATM accumulation is a marker of metabolic disease.
Genetic Overexpression of sgp130Fc Increases
Adipogenesis in Response to High-Fat Feeding
While IL-6/mice are protected from a variety of pro-inflamma-
tory diseases, such as RA (Alonzi et al., 1998), hepatocellular
carcinoma (Naugler et al., 2007), and colitis (Gay et al., 2006),
they paradoxically display mature-onset obesity, hepatosteato-
sis, liver inflammation, and insulin resistance (Matthews et al.,
2010; Wallenius et al., 2002). Sgp130Fc transgenic mice show
high serum levels of sgp130Fc (Figure S1A) resulting in impaired
IL-6 trans-signaling but intact, membrane-bound IL-6R signaling
and protection from inflammation (Rabe et al., 2008). However,
the metabolic phenotype of these mice is unknown. Sgp130Fc
mice displayed normal body mass, fat mass and lean mass,
glucose tolerance (FiguresS1BandS1C), food intake, andenergy
expenditure (data not shown) comparedwith wild-type (WT) con-
trol mice. Next, we placed the mice on either a standard chow
or HFD (42% of calories from fat) for a period of 12 weeks. As
expected, the HFD increased both body mass and fat mass
compared with chow-fed animals (Figures 2A and 2B; Figures
S1D and S1E). Consistent with the phenotype of the IL-6/
mice (Matthews et al., 2010; Wallenius et al., 2002), sgp130Fc
mice fed a HFD displayed a greater body mass and fat mass
compared with WT and a decrease in lean mass in response to
the HFD (Figures 2A and 2B; Figures S1D and S1E). As expected,
energy intakewashigher in response to theHFD,but hyperphagia
was not responsible for the higher bodymass and fat mass in the
sgp130Fc mice (Figure 2C). Rather, this phenotype was due to a
decrease in energy expenditure as measured by both oxygen
consumption (VO2) (Figure 2D) and the change in body weight in
response to an overnight fast (Figure S1G). In addition, locomotor
activity was decreased by both consumption of HFD and expres-
sion of sgp130Fc (Figure S1F). It is generally accepted that fewer
and larger adipocytes are characteristic of metabolic dysregula-
tion in obesity. Accordingly, we next examined the adipose tissue
beds in detail. In linewith our in vivomeasures, epididymal fat pad
mass was higher in the sgp130Fc mice irrespective of diet (Fig-
ure 2E), while serum leptin was higher in the sgp130Fc mice on
theHFD (FigureS1H). Importantly, however, and indirect contrast
Figure 1. The Soluble IL-6 Receptor Correlates with White Adipose Tissue Macrophage Accumulation and Insulin Action in Obesity and
Mediates Macrophage Migration
(A and B) The mRNA expression of the macrophage marker cluster of differentiation 68 (CD68) and the metalloproteinase ADAM17 (A) in white adipose tissue
(WAT), and the plasma concentration of the soluble IL-6 receptor (sIL-6R) and the soluble gp130 (B) in lean (Lean); obese, impaired glucose tolerance (IGT); and
type 2 diabetes (T2D) patients. *p < 0.05 denotes difference from lean (n = 6 per group). Data are expressed as mean ± SEM.
(C–H) Correlations between HOMA-IR and WAT CD68 mRNA (C), HbA1c and WAT CD68 mRNA (D), HOMA-IR and sIL-6R (E), and HbA1c and sIL-6R (F) body
mass and sIL-6R (G) and WAT CD68 mRNA and sIL-6R (H) in all patients. Correlative analyses (Pearson) were performed using a two-tailed p value (n = 18).
(I) Bone marrow-derived macrophages from C57BL/6 mice were cultured, and their migration was measured in response to increasing doses of MCP-1, Hyper-
IL-6 (the designer cytokine consisting of IL-6 and the sIL-6R joined by a peptide linker), and/or sgp130Fc. Three technical replicates performed in three
independent experiments are shown. Data are expressed as mean ± SEM. * denotes p < 0.05 compared with non-treated control; y denotes p < 0.05 compared
with Hyper-IL-6 (10 or 25 ng/ml).
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Figure 2. Metabolic Phenotyping of sgp130Fc Mice
(A and B) Total body mass progression during 12-week dietary period (A) and pre- and post-total body mass, fat mass, and lean mass (B). n = 33–52 animals.
(C and D) Average daily food (energy) (C) and oxygen (VO2) consumption (D). In (D), the shaded area denotes dark cycle and the solid line denotes a.m. n = 5–11
cages per group (C); n = 5–6 cages per group (D).
(E and F) Epididymal fat pad mass (E) and adipocyte area and number (F). n = 24–39 (E); n = 14–27 (F).
(G andH) Histogram of adipocyte cross-section area averaged from 203magnified fields per section (G) and themRNA expression of CCAAT1/enhancer-binding
protein beta (C/EBPb), fatty acid-binding protein 4 (FABP4), vascular endothelial factor alpha (VEGFa), cluster of differentiation 31 (CD31), and hypoxia-inducible
factor alpha (HIF1a) (H) in sgp130Fc andWTmice fed a chow diet or HFD for 12 weeks. * denotes main effect (p < 0.05) for diet. y denotesmain effect (p < 0.05) for
genotype. Data are expressed as mean ± SEM. n = 14–27 (G); n = 5–19 (H).
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Figure 3. Adipogenic Gene Expression in
IL-6 Knockout Mice and Microarray Anal-
ysis of IL-6 KO versus sgp130 Transgenic
Animals
(A)mRNAexpressionofCCAAT1/enhancer-binding
protein beta (C/EBPb), vascular endothelial factor
alpha (VEGFa), fatty acid-binding protein4 (FABP4),
cluster of differentiation 31 (CD31), and hypoxia-
inducible factor alpha (HIF1a) in IL-6 KO and WT
mice fed a chow diet or HFD for 12weeks. n = 6 per
group. Data are expressed as mean ± SEM.
(B) Enrichment score of gene ontology clusters
that were significantly enriched (i.e., enrichment
score cutoff of 2 corresponding to a p value cutoff
of 0.01) in the list of differentially expressed genes
between IL-6 KO and sgp130. n = 2–3 per group.
(C and D) Heatmap representation of expression
levels for all libraries of the top 50 upregulated and
top 50 downregulated genes selected from the
comparison of IL-6 KO versus sgp130. n = 2–3 per
group.with previous observation in IL-6/mice (Matthews et al., 2010),
the increase in adiposity was not due to adipocyte hypertrophy,
sincemean adipocyte areawas lower in the sgp130Fc compared
withWTmice (Figure 2F). Althoughwe did not detect a significant
increase in total adipocyte number per cross-sectional image
(Figure 2F), when we stratified the cross-sectional area, we
observed many smaller, but fewer larger, adipocytes in the
sgp130Fc compared with WT mice (Figure 2G). Together, these
data indicate that the increase in adipose tissue mass in the
sgp130Fc mice is due to increased adipogenesis rather than
adipocyte hypertrophy, as previously seen in IL-6/ mice (Mat-
thews et al., 2010). To determine a possible mechanism for the
current observation, we first examined serum adiponectin, a
peptide hormone known to induce adipose tissue expansion in
a manner similar to our observed phenotype (Kim et al., 2007),
but this was not different when comparing mice (Fig-
ure S1H). We next examined the mRNA expression of several
genes involved in adipogenesis and differentiation. CCAAT1/
enhancer-binding protein beta (C/EBPb) is known to regulate adi-
pogenesis and was higher in sgp130Fc compared withWTmice,
as was the mRNA expression of fatty acid-binding protein 4
(FABP4), known to regulate adipocyte differentiation (Figure 2H).
In addition, since angiogenesis modulates adipogenesis (Cao,Cell Metabolism 21, 403–42007), we also examined the mRNA
expression of vascular endothelial factor
alpha (VEGFa), cluster of differentiation
31 (CD31), and hypoxia-inducible factor
alpha (HIF1a), all implicated in theprocess
of angiogenesis. ThemRNAexpression of
all threegeneswashigher in the sgp130Fc
compared with WT mice (Figure 2H).
It was clear from these data that the etiol-
ogy of the increase in adiposity when
comparing the IL-6/ with the sgp130Fc
mice was different, as the former dis-
played adipocyte hypertrophy (Matthews
et al., 2010) while in this study the
sgp130Fc mice displayed an increase inadiposity consistent with adipogenesis. Accordingly, we next
performed a detailed comparison of adipose tissue gene expres-
sion between the two strains of mice. First, we retrospectively
examined the mRNA expression of the genes presented in
Figure 2H in adipose tissue samples from the IL-6/ mice. In
contrast with the observations in the sgp130Fc mice, deletion of
IL-6 had no effect on the expression of any of these genes (Fig-
ure3A).Nextweperformedgenearrayanalysesonadipose tissue
samples fromWT, IL-6/mice and sgp130Fc mice. The pattern
of gene expression was markedly different when comparing
the IL-6/with the sgp130Fcmice (Figures 3B–3D). Importantly,
geneontologyanalyses revealed thatgenes involved inangiogen-
esis produced the second-highest enrichment score (Figure 3B).
Taken together, these data demonstrate that overexpression of
sgp130Fc, but not deletion of IL-6, results in increased adipogen-
esis leading to increased fat pad mass due to an increased num-
ber of smaller adipocytes in response to a HFD.
Genetic Overexpression of sgp130Fc Does Not
Exacerbate Liver Steatosis or Glucose Intolerance
Complete ablation of IL-6 signaling in the liver either via genetic
deletion of IL-6 (Matthews et al., 2010) or via liver-specific dele-
tion of the IL-6 receptor (Wunderlich et al., 2010) results in16, March 3, 2015 ª2015 Elsevier Inc. 407
Figure 4. sgp130 Overexpression Prevents
High-Fat Diet-Induced White Adipose Tis-
sue Macrophage Accumulation
(A and B) sgp130Fc concentration (A) and mRNA
expression of EGF-like module-containing mucin-
like hormone receptor-like 1 (EMRI-gene encoding
F4/80) and cluster of differentiation 68 (CD68) (B) in
white adipose tissue (WAT).
(C and D) Representative cross-sectional immu-
nohistochemical stain of F4/80 (C) and quantifi-
cation of F4/80 in crown-like structures (D) in WAT.
(E and F) Representative plot (E) and quantification
(F) of F4/80 and CD11c positive (+) cells by flow
cytometry.
(G) The mRNA expression of monocyte chemo-
attractant protein-1 (MCP-1), tumor necrosis fac-
tor-a (TNF-a), interleukin-6 (IL-6), interleukin-1-b
(IL-1b) and Nod-like receptor protein 3 (NLRP3) in
WAT in sgp130Fc and WT mice fed a chow diet or
HFD for 12 weeks (except in E and F, where only
HFD data were measured). * denotes main effect
(p < 0.05) for diet; y denotes main effect (p < 0.05)
for genotype; z denotes difference (p < 0.05)
between WT and sgp130Fc on HFD.
Data are expressed as mean ± SEM. n = 6–21
(A–G).hyperlipidemia, increased hepatosteatosis, and liver inflamma-
tion and damage when mice are fed a HFD. Accordingly, we
next examined whether this was the case when only IL-6 trans-
signaling is blocked. Selective blockade of IL-6 trans-signaling
did not exacerbate HFD-induced increases in circulating
non-esterified fatty acid concentration (data not shown), hepa-
tosteatosis, liver inflammation, or liver function (Figures S2A–
S2F). Furthermore, and in contrast with IL-6/ mice (Matthews
et al., 2010), sgp130Fc mice did not display glucose intolerance
relative to WT mice (Figure S2G).
Genetic Overexpression of sgp130Fc Ameliorates
Adipose Tissue Macrophage Accumulation in Response
to High-Fat Feeding
As we demonstrated in Figure 1, the sIL-6R appeared to be a
major chemotactic signal in humans, and IL-6 trans-signaling-408 Cell Metabolism 21, 403–416, March 3, 2015 ª2015 Elsevier Inc.induced chemotaxis was blocked by
treatment with sgp130Fc in vitro. Accord-
ingly, we next examined whether this link
persisted in the sgp130Fc mice. Consis-
tent with our data in humans, the HFD
induced an increase in serum sIL-6R (Fig-
ure S3A). The mRNA expression of the IL-
6R decreased, while ADAM10 increased
in WAT (Figure S3B). The systemic over-
expression of sgp130Fc resulted in a
marked accumulation of sgp130Fc pro-
tein in the WAT (Figure 4A), but this did
not affect serum sIL-6R concentration,
nor the mRNA expression of either the
IL-6R or ADAM10 in WAT (Figure S3B).
Strikingly, and consistent with our hy-
pothesis, overexpression of sgp130Fcameliorated the ATM accumulation. While the HFD induced
marked increases in themRNA abundance of Emr1, the gene en-
coding F4/80, and Itgax, the gene encoding CD11c, these in-
creases were abrogated in the sgp130Fc mice (Figure 4B). We
next examined the protein expression of F4/80 within WAT by
two independent methods, immunohistochemistry and flow cy-
tometry. While the HFD increased the appearance of crown-
like structures 4-fold in the WAT of WT mice, this increase
was abrogated in sgp130Fc mice (Figures 4C and 4D). In addi-
tion, the percentage of cells positively stained for both F4/80
and CD11c in the WAT of mice fed the HFD was markedly lower
in the sgp130Fc compared with WT mice (Figures 4E and 4F).
Fibrosis is associated with the appearance of crown-like struc-
tures and inflammation in WAT and systemic insulin resistance
(Halberg et al., 2009). Accordingly, we also measured collagen
content using picro-sirius red staining in WAT. Collagen staining
in WAT was increased in WT but not in sgp130Fc mice in
response to HFD (Figures S3D and S3E). These data suggest
that transgenic expression of sgp130Fc can prevent macro-
phage accumulation and fibrosis in WAT of mice fed a HFD. It
is well known that macrophages release pro-inflammatory cyto-
kines that can signal in neighboring adipocytes to activate serine
threonine kinases such as inhibitor of kappa B kinase (IKKb) and
c-Jun NH2-terminal kinase (JNK) to impair insulin action (Wellen
and Hotamisligil, 2003). Accordingly, we next examined these
pathways. We first measured MCP-1 and observed an increase
in the mRNA expression of this gene in WAT of mice fed a HFD
but, critically, no difference when comparing genotypes (Fig-
ure 4G), indicating that the expression ofMCP-1was not respon-
sible for the lack of ATM in sgp130Fc mice. As expected,
the mRNA expression of TNF-a was increased in mice
fed HFD, but—somewhat unexpectedly—this increase was not
decreased in sgp130Fc mice (Figure 4G), despite the fact that
the increase in HFD-induced ATM accumulation was prevented.
Although the HFD led to mild increases in the phosphorylation of
IKK and JNK (p = 0.057), this was unaffected by genotype (Fig-
ures S3F and S3G). Somewhat unexpectedly, themRNA expres-
sion of IL-6, IL-1b, and Nod-like receptor protein 3 (NLRP3) in
WAT were all elevated in the sgp130Fc mice (Figure 4G), despite
the near absence of ATM. These increases appeared not to
affect circulating cytokine expression, as we observed neither
a diet or genotype effect on circulating IL-6, IL-1b, IL-10, or
TNF-a measured in serum by multiplex ELISA (data not shown).
A ‘‘macrophage-centric’’ view of obesity-associated inflamma-
tion has reigned for several years, despite the fact that many
other immune cell types play an important role in obesity-asso-
ciated WAT inflammation (Mathis, 2013). As this is an important
consideration, we next examined the immune cell milieu in both
the WAT and circulation. As previously shown (Feuerer et al.,
2009;Wu et al., 2011), we observed decreases in the percentage
of leukocytes staining positive for eosinophils (Figures 5A and
5E). In addition, as previously demonstrated (Nishimura et al.,
2009), the HFD increased the percentage of lymphocytes
stained positively for CD8, but not CD4, T cells (Figures 5B and
5E). It has been suggested that a HFD increases both neutrophils
and B cells within WAT, the former of which releases the enzyme
elastase to induce insulin resistance (Talukdar et al., 2012).
In contrast with these findings, we observed a HFD-induced
decrease in both the percentage of leukocytes staining positively
for neutrophils (Figures 5A and 5E) and B cells (Figures 5C and
5E) and a similar decrease in the mRNA expression of ELANE,
the gene encoding elastase (Figure S3H). Importantly, however,
unlike ATM, the overexpression of sgp130Fc had no effect on
any of these measures in WAT of mice irrespective of the diet
(Figures 5A–5C and 5E; Figure S3H). Regulatory T cells (Tregs)
have emerged as important negative regulators of WAT inflam-
mation and metabolic homeostasis (Cipolletta et al., 2012;
Feuerer et al., 2009). Accordingly, we next examined the accu-
mulation of Tregs in the adipose tissue of the mice. Within the
time frame of our experiment, we did not observe a HFD-induced
decrease in Tregs in WT mice, but did so in sgp130Fc mice (Fig-
ures 5D and 5E). In addition, we observed a decrease in FoxP3
mRNA in WAT of sgp130Fc mice (Figure S3H). We next exam-
ined a set of immune cells in the blood of the mice (Figures
S4A–S4C). Although not statistically significant, overexpressionCeof sgp130Fc tended to increase the percentage of macrophages
in the blood (Figure S4A), a result consistent with the blocking of
migration of macrophages from the blood to the WAT. The per-
centages of monocytes, natural killer T cells, and B cells as well
as hemoglobin, hematocrit, and red blood cell numbers were
affected by neither diet nor genotype (Figures S4A–S4C). The
HFD decreased the percentage of CD8 cells (Figure S4A) and
increased the platelet count (Figure S4B) irrespective of geno-
type. In general terms, the immune status of the sgp130Fc
mice was normal.
sgp130Fc Drug Therapy Regresses High-Fat
Diet-Induced ATM Accumulation but Does Not Affect
Insulin Resistance
Our data in the sgp130Fc mice provided a strong rationale for
testing whether sgp130Fc could be used as a drug therapy to
treat ATM accumulation and whether this influenced insulin
resistance. We deemed the transgenic mouse a less than ideal
model to test the efficacy of sgp130Fc therapy. Since the trans-
gene was expressed shortly after birth, the accumulation of ATM
would have been prevented from the onset of obesity, which
does not occur in human treatment interventions for metabolic
disease. Accordingly, we next performed a drug intervention trial
in C57BL/6 mice (protocol summarized in Figure S5A). Briefly,
four groups of mice were studied from 8 weeks of age. Three
groups were administered a HFD, while the fourth received a
regular chow diet. After 12 weeks of diet, the chow-fed animals
(Chow Control) and one HFD group (HFD Basal) were killed. The
remaining groups were treated with either 0.5 mg/kg sgp130Fc
protein (HFD Sgp130Fc) or sham control (HFD Saline) twice
weekly for a further 6 weeks. The dosing regime was based on
pharmacokinetics of sgp130 (Figure 6A). Unlike the transgenic
model reported above, while the HFD increased total body
mass and fat mass, no differences were observed between the
HFD saline, basal, or sgp130Fc in these measures (Figure 6B)
either during the dietary intervention or during the drug treatment
(Figures S5B and S5C). Lean mass was not different across
groups (Figure 6B; Figure S5D). In contrast to the study in
sgp130Fc transgenic mice, we observed no differences in
epididymal fat pad mass (Figure 6C) or adipocyte number (Fig-
ure 6E; Figure S5E) across groups. We also examined a number
of inflammatory genes in the adipose tissue and liver from the
mice and circulating cytokines. In general, the HFD increased
or tended to increase the expression of all measured genes in
the adipose tissue, but notably, sgp130Fc treatment reduced
or tended to reduce HFD-induced increases in these genes, indi-
cating that sgp130Fc treatment was indeed anti-inflammatory in
adipose tissue (Figure S5F). We observed no such effects in liver
or circulating cytokines (Figures S6A and S6B). Consistent with
our study in the sgp130Fc transgenic mice, the HFD increased
serum sIL-6R concentration (Figure S5G), and importantly, we
observed a marked regression of ATM in response to 6 weeks
of sgp130Fc treatment as measured by the mRNA expression
of Emr1 and Itgax (Figure 6D) and the appearance of F4/80
measured by immunohistochemical detection in adipose tissue
cross-sections (Figures 6E and 6F). Given the efficacy in regres-
sion of ATM without affecting adipose tissue morphology with
sgp130Fc treatment, we next performed hyperinsulinemic-
euglycemic clamps in the mice. While the glucose infusion ratell Metabolism 21, 403–416, March 3, 2015 ª2015 Elsevier Inc. 409
Figure 5. sgp130 Overexpression Has Mini-
mal Effects on High-Fat Diet-Induced Modifi-
cation of Immune Cells in White Adipose
Tissue
(A–D) Stromal vascular cells were isolated from
epididymal white adipose tissue (WAT) and as-
sessed by flow cytometry. Levels of eosinophils and
neutrophils as a percentage of total leukocytes (A),
levels of cytotoxic CD8+ and CD4+ T cells as a
percentage of total lymphocytes (B), levels of B cells
as a percentage of total leukocytes (C), and levels of
regulatory T cells (Tregs) as a percentage of CD4+
T cells (D) are shown. All cells were first gated of
CD45+ cells. Eosinophils were sorted as Siglec F+
and neutrophils as Gr1hi. T cells were sorted as
TCRb+, CD4+, or TCRb+. CD8+ B cells were sorted
as TCRb or CD19+. Tregs were sorted as TCRb+,
CD4+, or FoxP3+
(E) Quantification of all cell populations as % parent
cell populations. * denotes main effect (p < 0.05) for
diet; z denotes difference (p < 0.05) between WT
and sgp130Fc on HFD.
Data are expressed as mean ± SEM. n = 6–9 (A–E).
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Figure 6. Six Weeks of sgp130Fc Treatment
Period Decreases Adipose Tissue Macro-
phage Accumulation but Does Not Improve
Markers of Insulin Sensitivity in Mice Fed
a HFD
(A) Pharmacokinetic profile of sgp130Fc in the
blood of mice after a single (0.5 mg/kg) injection
(A). n = 5–12.
(B–D) The change in total, fat, and lean mass (B),
epididymal fat pad mass (C), and mRNA expres-
sion of EGF-like module-containing mucin-like
hormone receptor-like 1 (EMRI-gene encoding
F4/80) and integrin alpha X chain protein (Itgax;
gene encoding CD11c) (D) in white adipose tissue
(WAT). n = 9–13.
(E and F) Adipocyte number (E) and representative
cross-sectional immunohistochemical stain of
F4/80 (F) and quantification of F4/80 represented
as the number of crown-like structures (CLS) per
adipocyte in WAT from C57BL/6 mice fed a chow
diet or HFD during the dietary and during the drug
intervention period, which involved twice weekly
injections of sgp130Fc (0.5 mg/kg) or saline. n =
9–11.
(G and H) The glucose infusion rate (GIR), glucose
disposal rate (GDR), and percent suppression of
hepatic glucose production (HGP) (G) and the rates
of 2-deoxyglucose uptake (Rg’) in visceral white,
subcutaneous white, and brown (BAT) adipose
tissue (H) during a hyperinsulinemic-euglycemic
clamp in C57BL/6 mice fed a chow diet or HFD the
entire intervention period. * denotes difference (p <
0.05) from chow control. z denotes difference (p <
0.05) from HFD saline. n = 10–13.
Data expressed as mean ± SEM.(GIR) was reduced 2-fold by the HFD, the sgp130Fc treatment
had no effect in rescuing insulin sensitivity despite the marked
ATM regression (Figure 6G; Figures S5H, S5I, and S6C–S6E).
Moreover, this pattern was observed for both glucose disposal
rate (GDR; Figure 6G) and the suppression of glucose production
during the clamp (HGP; Figure 6G). In addition, the sgp130Fc
treatment did not affect plasma NEFA concentration or the
percent suppression of lipolysis during the clamp (Figures S6F
and S6G). As discussed, ATMs are thought to release cytokines
that interfere with insulin action in neighboring adipocytes
(Wellen andHotamisligil, 2003), andwe have previously detected
changes in adipose tissue insulin sensitivity in the absence of
changes in whole-body insulin action when we have genetically
modified myeloid cells in vivo (Nicholls et al., 2011). Accordingly,
we measured tissue/organ-specific glucose uptake during the
clamp using 2-deoxyglucose (termed Rg’) (Turner et al., 2013)
to determine whether adipose tissue per se was protected
from insulin resistance induced by the HFD with sgp130Fc treat-Cell Metabolism 21, 403–4ment. Despite the marked ATM regres-
sion in adipose tissue beds, the Rg’ in
visceral and/or subcutaneous WAT, or
indeed in BAT, was not improved by
sgp130Fc treatment (Figure 6H). Taken
together, these data clearly show that
6 weeks of treatment with sgp130Fccan largely ameliorate HFD-induced ATM accumulation, but
this does not affect metabolic homeostasis.
Prevention of ATM Accumulation in sgp130Fc
Transgenic Mice Does Not Improve Insulin Sensitivity
The results from our drug intervention study clearly demon-
strated that more than a 2-fold regression in ATM after the onset
of obesity had no effect on HFD-induced insulin resistance or
glucose intolerance. However, it is possible that only prevention
of ATM accumulation, rather than regression of ATM once accu-
mulated, may protect against insulin resistance. In addition, in
the treatment study the reduction in macrophage accumulation
with treatment was not as marked as was observed in the
sgp130Fc mouse study. Accordingly, we next studied a subset
of sgp130Fc mice, carefully matched to WT mice for total body
mass and fat mass, to remove differences in these parameters
as confounding measures (Figure 7A). Although this cohort of
mice was matched for adiposity, the HFD-induced increase in16, March 3, 2015 ª2015 Elsevier Inc. 411
Figure 7. sgp130Fc Transgenic Mice Have
Decreased Adipose Tissue Macrophage
Accumulation but Unaltered Insulin Sensi-
tivity Compared with Weight-Matched
Control Mice
(A–D) Total, fat, and lean mass (A), mRNA
expression of EGF-like module-containing mucin-
like hormone receptor-like 1 (EMRI-gene encoding
F4/80) and integrin alpha X chain protein (Itgax;
gene encoding CD11c) in white adipose tissue
(WAT) (B), representative cross sectional immu-
nohistochemical stain of F4/80 (C), and plasma
glucose during an oral glucose tolerance test (D).
Data are expressed as mean ± SEM, n = 6–9.
(E and F) The glucose infusion rate (GIR), glucose
disposal rate, and percent suppression of hepatic
glucose production (HGP) (E) and the rates of
2-deoxyglucose uptake (Rg’) in visceral white,
subcutaneous white, and brown (BAT) adipose
tissue (F) during a hyperinsulinemic-euglycemic
clamp in C57BL/6 mice fed a chow diet or HFD
during the dietary and during the drug intervention
period. * denotes main effect (p < 0.05) for diet.
y denotes main effect (p < 0.05) for genotype.
z denotes difference (p < 0.05) between WT and
sgp130Fc on HFD. Data are expressed as mean ±
SEM, n = 6–9.ATM, as measured by the mRNA abundance of EmR1 and Itgax
(Figure 7B), and the appearance of crown-like structures in adi-
pose tissue cross-sections (Figure 7C) was prevented in the
sgp130Fc mice. Despite this prevention, the HFD-induced intol-
erance (Figure 7D) was not improved. Moreover, GIR, GDR, and
HGP (Figure 7E) during a hyperinsulinemic-euglycemic clamp
were not different when comparing the sgp130Fc with WT
mice. In addition, the HFD-induced decrease in WAT and BAT
glucose uptake was not improved in sgp130Fc mice (Figure 7F),
despite the complete prevention of ATM accumulation.
DISCUSSION
There are several important findings in our study. These include
the metabolic phenotype of the sgp130Fc mice, the identifica-
tion of the sIL-6R as a chemotactic signal in regulating ATM412 Cell Metabolism 21, 403–416, March 3, 2015 ª2015 Elsevier Inc.accumulation, and the observation that
pharmacological therapies that target
ATM accumulation appear ineffective in
protection against insulin resistance.
We previously showed that very high
concentrations of sgp130Fc, in the pres-
ence of murine sIL-6R, can block classic
IL-6 signaling (Garbers et al., 2011). How-
ever, in this previous study, mice were
also injected with IL-6 and sgp130Fc
at doses comparable to the present
study. In this circumstance, IL-6 classical
signaling through membrane-bound IL-
6Rwas intact, asprovenby theconserved
phosphorylation of STAT3 in hepato-
cytes, indicating that sgp130Fc in vivoonly blocks IL-6 trans-signaling and not classical IL-6 signaling.
This notion is strengthened by the comparison between IL-6/
and sgp130Fc mice. Apart from the reduced ATM observed in
the WAT of the sgp130Fc mice, they displayed no hallmarks of
adverse metabolic homeostasis, in direct contrast with IL-6/
mice that have liver inflammation and insulin resistance (Mat-
thews et al., 2010). The differences when comparing the
sgp130Fc with the IL-6/ mice have major ramifications for the
development of therapeutics to treat inflammatory disease.While
tocilizumab is a very effective treatment for RA (Nishimoto et al.,
2005; Smolen et al., 2008), weight gain, hypercholesterolemia,
hyperlipidemia, and bacterial infection are noted side effects
(Febbraio et al., 2010). In contrast, in the current study, selective
blockade of IL-6 trans-signaling prevented ATM accumulation,
but critically did not result in these adverse metabolic side ef-
fects. In contrast with the IL-6/ mice (Matthews et al., 2010),
sgp130Fc mice displayed an increase in smaller adipocytes and
a corresponding decrease in larger adipocytes, which is a hall-
mark of adipogenesis and improved metabolic health (Figures 3
and 4). Microarray analyses revealed a very different pattern of
adipose tissue gene expression with gene ontology analyses,
showing that angiogenesis produced the second-highest enrich-
ment score (Figure 3B). It should also be noted that the sgp130Fc
mice display reduced locomotor activity on the HFD, which may
also contribute to the slightly greater adiposity (Figure S1F),
whereas the IL-6/ mice did not show any such differences
(Matthews et al., 2010). In addition, unlike IL-6/ mice, which
display hepatosteatosis and liver inflammation even when fed a
chow diet (Matthews et al., 2010), the sgp130Fc mice do not
exhibit a negative metabolic phenotype whether they are fed a
chowdiet or HFD.Given these results, we suggest that sgp130Fc
may present a viable therapeutic treatment option for inflamma-
tory diseases where IL-6 blockade is effective, because the
unwanted metabolic side effects of complete ablation of IL-6
signaling may be prevented. This is particularly important since
patients treated for inflammatory diseases must be medicated
for several years, as currentmedications do not cure the disease.
Even in diseases such as RA, where initial weight gain may not
pose a problem, weight gain over several years inevitably leads
to adverse changes in metabolic homeostasis. A drug that will
have efficacy but not result in weight gain would be particularly
advantageous for such diseases.
MCP-1, primarily responsible for monocyte/macrophage
chemotaxis in inflammatory diseases and atherosclerosis (Charo
et al., 1994), is also thought to mediate monocyte/macrophage
migration into WAT in obesity (Kamei et al., 2006; Kanda et al.,
2006). Accordingly, MCP-1 inhibitors have been the subject of
much interest, resulting in the development of mNOX-E36, a
so-called Spiegelmer that binds MCP-1 with high affinity and
neutralizes its action (Kulkarni et al., 2007). While mNOX-E36
has shown efficacy in mouse models of lupus nephritis (Kulkarni
et al., 2007), liver fibrosis (Ehling et al., 2014), and diabetic kidney
disease (Darisipudi et al., 2011), there are no reports of efficacy
using mNOX-E36 in preventing ATM accumulation. Based on
previous findings in MCP-1-deficient mice (Inouye et al., 2007;
Kirk et al., 2008) and our current findings, this is not surprising.
In the current study, we identify IL-6 trans-signaling as a major
mediator of ATM accumulation. Importantly, Hyper-IL-6 induced
marked macrophage migration in a dose-dependent manner,
which was completely blocked in the presence of sgp130Fc.
These data, in conjunction with the reduction of ATM accumula-
tion in sgp130Fc mice, demonstrate that IL-6 trans-signaling
is directly responsible for mediating ATM recruitment. Thus,
together with our in vivo data, we have identified IL-6 trans-
signaling as a major mechanism of ATM accumulation.
Despite the prevailing dogma that HFD-induced ATM
accumulation contributes to insulin resistance, our data clearly
demonstrate that prevention of ATM accumulation both geneti-
cally and pharmacologically appears not to be a viable strategy
for the treatment of insulin resistance and/or T2D.While these re-
sults appear at odds with previous studies that have adopted
different strategies to ablate macrophages, there are several
important differences between our study and those performed
previously (Feng et al., 2011; Patsouris et al., 2008). First and
foremost, previous studies used strategies to completely ablateCeeither all (Feng et al., 2011) or selectively ‘‘M1-like’’ (Patsouris
et al., 2008) macrophages. Our study employed a drug interven-
tion strategy to prevent ATM accumulation, rather than ablation
of macrophages. From a therapeutic point of view, ablation of
macrophages to treat metabolic disease is not a viable strategy,
as it would severely compromise immunity. Hence, our data are
of major significance for the development of drugs to treat T2D.
Based on our data, it is likely that in previous studies where
macrophages have been ablated (Feng et al., 2011; Patsouris
et al., 2008), improved insulin action was mediated by effects
of macrophage independent of the adipose tissue.
As outlined above, our pre-clinical data suggest that devel-
oping drugs that target ATM chemotaxis is an ineffective thera-
peutic strategy to treat insulin resistance and T2D. There are,
however, some important considerations to these findings. First,
although macrophages have been recognized for some time
as being a hallmark of adipose tissue inflammation (Weisberg
et al., 2003; Xu et al., 2003), it is now acknowledged that many
other cells of the innate and adaptive immune system are also
an important part of the immunological milieu of adipose tissue
in obesity (Mathis, 2013). Thus, it is the balance of pro- and
anti-inflammatory immune cells that is important for the regula-
tion of obesity-induced adipose tissue inflammation and insulin
resistance (Mathis, 2013). Therefore, one possibility is that
marked reduction of all adipose tissue macrophages, as in our
study is ineffective, asmetabolic parameters may be determined
by the balance of M1 to M2 macrophages. Furthermore, while
sgp130Fc was strikingly effective in preventing ATM accumula-
tion, it had little effect on other immune cell changes seen with
HFD-induced weight gain (Figure 5). Our data highlight the fact
that adipose tissue inflammation is far more complex than simply
a function of ATM accumulation. Furthermore, it is important to
consider that the results from our intervention studies in mice
may not be readily transferred to human obesity. This is an
especially important point, as we observed in our patient group
convincing correlations between insulin resistance (asmeasured
by the HOMA-IR), sIL-6R plasma concentrations, and ATM
accumulation (as measured by CD68 transcripts). Therefore, it
remains possible that blocking IL-6 trans-signaling in humans
may have clinical utility that goes beyond the prevention of
ATM accumulation. This is a particularly important consideration
because sgp130Fc Phase I clinical trials have been completed,
with Phase II trials about to commence.
In conclusion, we demonstrate that IL-6 trans-signaling is ama-
jor chemotactic signal inATMrecruitment.AlthoughATMaccumu-
lation is blocked by sgp130Fc treatment, it does not improve insu-
lin resistance. However, given the fact that sgp130Fc mice do not
present with a negative metabolic phenotype, while nonetheless
possessing anti-inflammatory properties, our data suggest that
sgp130Fc treatment may be a more favorable treatment option
for inflammatory diseases such as RA compared with current
treatments that negatively impact upon metabolic homeostasis.
EXPERIMENTAL PROCEDURES
Mouse Models
Mice that overexpress human sgp130Fc were generated as previously
described (Rabe et al., 2008). Heterozygous animals were bred together and
litters were genotyped. Animals negative for the transgene were designated
WT, and animals expressing the transgene were bled for ELISA analysis, asll Metabolism 21, 403–416, March 3, 2015 ª2015 Elsevier Inc. 413
genotyping cannot distinguish between homozygous and heterozygous mice.
Mice exhibiting a human sgp130Fc circulating concentration of >10 mg/ml
were considered homozygous, while animals testing positive, but below that
threshold, were considered heterozygous. Littermate WT and homozygous
mice were bred in parallel, and their litters were used for the study. Sgp130Fc
transgenic and C57BL/6 mice were bred and housed at the Alfred Medical
Research and Education Precinct Animal Centre (AMREP PAC) in a path-
ogen-free facility under controlled environmental conditions and exposed to
a 12:12 hr light:dark cycle. IL-6/ mice were generated as previously
described (Matthews et al., 2010). Animal experiments were approved by
the Alfred Medical Research and Education Precinct Animal Ethics Committee
and conducted in accordance with the National Health and Medical Research
Council (NHMRC) of Australia Guidelines for Animal Experimentation. All ex-
periments commenced when mice were 6–8 weeks of age. Mice were fed
either a chow diet (5% of total energy from fat) or a HFD (43% of total energy
from fat) for 12–18 weeks depending on the experiment. Animals were given
their prescribed diet and water ad libitum.
Metabolic Measurements
Plasma Measurements
ELISAs were performed for the soluble IL-6 receptor (DuoSet mouse IL-6 sR
ELISA Kit, DY1830), total adiponectin (Quantikine Mouse Adiponectin/
Acrp30, MRP300), and leptin (Quantikine Mouse/Rat Leptin, MOB00) (all
from R&D Systems) according to the manufacturer’s specifications. Insulin
concentrations were measured using a Mouse Ultrasensitive Insulin ELISA
kit (ALPCO) according to the manufacturer’s instructions.
EchoMRI
Mouse body composition (fat mass [FM] and lean body mass [LBM]) was
measured weekly with a 4-in-1 EchoMRI body composition analyzer (Colum-
bus Instruments) and standard laboratory scales.
GTT
Intraperitoneal glucose tolerance tests (ipGTTs) (1 g/kg LBM) were performed
in 5 hr-fasted mice as previously described (Matthews et al., 2010). Oral GTTs
(2 g/kg LBM) were performed in 5 hr-fasted mice.
Hyperinsulinemic-Euglycemic Clamps
Hyperinsulinemic-euglycemic clamp studies were performed in mice 4 days
after catheterization. Details of the surgical procedures, insulin clamp, and
the determination of plasma and tissue radioactivity are described elsewhere
(Bruce et al., 2012).
Indirect Calorimetry
Oxygen consumption (VO2) and activity (beam breaks) were measured using a
12-chamber indirect calorimeter (Oxymax series) with an airflow of 0.6 l/min.
Statistical Analysis
Data are presented as mean ± standard error of the mean (SEM). Two-way
analysis of variance (ANOVA) was used to detect main effects for diet (chow
versus HFD) and genotype (WT versus sgp130Fc). Post-hoc analyses
(Holm-Sidak) were performed when a significant interaction effect occurred.
When not using a two-way ANOVA, one-way ANOVA or a Student’s t test
was used as reported in legends. Analyses were performed using a statistical
computer program (Sigma Stat Version 3.5). p < 0.05 was considered statisti-
cally significant.
ACCESSION NUMBERS
The Gene Expression Omnibus (GEO) accession number for the microarray
data reported in this paper is GSE63761.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2015.02.006.
AUTHOR CONTRIBUTIONS
M.J.K., T.L.A., S.R.-J., and M.A.F. conceived the study and designed the ex-
periments. M.J.K., H.L.K., T.L.A., V.D., D.A.W., A.J.M., A.V., and G.I.L. per-414 Cell Metabolism 21, 403–416, March 3, 2015 ª2015 Elsevier Inc.formed the immunological experiments. M.J.K., E.E., C.Y., S.R., C.R.B., and
R.S.L.-Y. performed the hyperinsulinemic-euglycemic clamp experiments.
M.J.K., H.L.K., D.C.H., V.B.M., B.N., L.P., W.S., C.R.B., and R.S.L.-Y.
performed the metabolic phenotyping experiments. X.-J.D., A.B., B.A.K.,
A.J.M., and A.K. contributed reagents, materials, and or analytical tools and
designed some of the experiments. M.J.K., H.L.K., and M.A.F. wrote the pa-
per. All authors discussed the data and commented on the manuscript before
submission.
ACKNOWLEDGMENTS
We thank Mr. Tim Gardner for his technical assistance and Dr. Georg Waetzig
for his help with the expression and purification of the sgp130Fc protein. This
work was supported by grants from the National Health & Medical Research
Council awarded to M.A.F., S.R.-J., and B.A.K. (NHMRC grant no. 526606,
APP1041760, APP1036352) and the Victorian Government Operational Infra-
structure Support scheme. The work of S.R.-J. was supported by the Deut-
sche Forschungsgemeinschaft (SFB654, project C5; SFB841, project C1;
SFB877, project A1 and the Cluster of Excellence ‘‘Inflammation at Inter-
faces’’). M.A.F., B.A.K., A.B., R.S.L.-Y., and C.R.B. are supported by Research
Fellowships from theNHMRC. A.K. is supported by a Sylvia andCharles Viertel
fellowship. A.J.M. is supported by a Diabetes Australia Research Trust Viertel
Award. D.C.H. is supported by a Skip Martin Fellowship of the Australian Dia-
betes Society. M.J.K. is supported by an Australian Post-Graduate Award and
BakerIDI Bright Sparks fellowships.
S.R.-J. is an inventor of patents owned by CONARIS Research Institute,
which develops the sgp130Fc protein together with Ferring Pharmaceuticals,
and he has stock ownership in CONARIS.
Received: August 18, 2014
Revised: December 21, 2014
Accepted: February 6, 2015
Published: March 3, 2015
REFERENCES
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De
Benedetti, F., Poli, V., and Ciliberto, G. (1998). Interleukin 6 is required for
the development of collagen-induced arthritis. J. Exp. Med. 187, 461–468.
Bruce, C.R., Risis, S., Babb, J.R., Yang, C., Kowalski, G.M., Selathurai, A., Lee-
Young, R.S.,Weir, J.M., Yoshioka, K., Takuwa, Y., et al. (2012). Overexpression
of sphingosinekinase1prevents ceramide accumulationandamelioratesmus-
cle insulin resistance in high-fat diet-fed mice. Diabetes 61, 3148–3155.
Cai, D., Yuan, M., Frantz, D.F., Melendez, P.A., Hansen, L., Lee, J., and
Shoelson, S.E. (2005). Local and systemic insulin resistance resulting from
hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183–190.
Cao, Y. (2007). Angiogenesis modulates adipogenesis and obesity. J. Clin.
Invest. 117, 2362–2368.
Carey, A.L., Steinberg, G.R., Macaulay, S.L., Thomas, W.G., Holmes, A.G.,
Ramm, G., Prelovsek, O., Hohnen-Behrens, C., Watt, M.J., James, D.E.,
et al. (2006). Interleukin-6 increases insulin-stimulated glucose disposal in hu-
mans and glucose uptake and fatty acid oxidation in vitro via AMP-activated
protein kinase. Diabetes 55, 2688–2697.
Chalaris, A., Gewiese, J., Paliga, K., Fleig, L., Schneede, A., Krieger, K.,
Rose-John, S., and Scheller, J. (2010). ADAM17-mediated shedding of
the IL6R induces cleavage of the membrane stub by gamma-secretase.
Biochim. Biophys. Acta 1803, 234–245.
Charo, I.F., Myers, S.J., Herman, A., Franci, C., Connolly, A.J., and Coughlin,
S.R. (1994). Molecular cloning and functional expression of two mono-
cyte chemoattractant protein 1 receptors reveals alternative splicing of the
carboxyl-terminal tails. Proc. Natl. Acad. Sci. USA 91, 2752–2756.
Cipolletta, D., Feuerer, M., Li, A., Kamei, N., Lee, J., Shoelson, S.E., Benoist,
C., and Mathis, D. (2012). PPAR-g is a major driver of the accumulation and
phenotype of adipose tissue Treg cells. Nature 486, 549–553.
Darisipudi, M.N., Kulkarni, O.P., Sayyed, S.G., Ryu,M., Migliorini, A., Sagrinati,
C., Parente, E., Vater, A., Eulberg, D., Klussmann, S., et al. (2011). Dual
blockade of the homeostatic chemokine CXCL12 and the proinflammatory
chemokine CCL2 has additive protective effects on diabetic kidney disease.
Am. J. Pathol. 179, 116–124.
Ehling, J., Bartneck, M., Wei, X., Gremse, F., Fech, V., Mockel, D., Baeck, C.,
Hittatiya, K., Eulberg, D., Luedde, T., et al. (2014). CCL2-dependent infiltrating
macrophages promote angiogenesis in progressive liver fibrosis. Gut. 63,
1960–1971.
Febbraio, M.A., Rose-John, S., and Pedersen, B.K. (2010). Is interleukin-6 re-
ceptor blockade the Holy Grail for inflammatory diseases? Clin. Pharmacol.
Ther. 87, 396–398.
Feng, B., Jiao, P., Nie, Y., Kim, T., Jun, D., van Rooijen, N., Yang, Z., and Xu, H.
(2011). Clodronate liposomes improve metabolic profile and reduce visceral
adipose macrophage content in diet-induced obese mice. PLoS ONE 6,
e24358.
Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J.,
Goldfine, A.B., Benoist, C., Shoelson, S., and Mathis, D. (2009). Lean, but
not obese, fat is enriched for a unique population of regulatory T cells that
affect metabolic parameters. Nat. Med. 15, 930–939.
Fischer, M., Goldschmitt, J., Peschel, C., Brakenhoff, J.P., Kallen, K.J.,
Wollmer, A., Gro¨tzinger, J., and Rose-John, S. (1997). I. A bioactive
designer cytokine for human hematopoietic progenitor cell expansion. Nat.
Biotechnol. 15, 142–145.
Garbers, C., Thaiss, W., Jones, G.W., Waetzig, G.H., Lorenzen, I., Guilhot, F.,
Lissilaa, R., Ferlin, W.G., Gro¨tzinger, J., Jones, S.A., et al. (2011). Inhibition of
classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which
is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
J. Biol. Chem. 286, 42959–42970.
Gay, J., Kokkotou, E., O’Brien, M., Pothoulakis, C., and Karalis, K.P. (2006).
Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic
acid-induced colitis in mice. Putative effect of antiinflammatory cytokines.
Neuroimmunomodulation 13, 114–121.
Halberg, N., Khan, T., Trujillo, M.E., Wernstedt-Asterholm, I., Attie, A.D.,
Sherwani, S., Wang, Z.V., Landskroner-Eiger, S., Dineen, S., Magalang,
U.J., et al. (2009). Hypoxia-inducible factor 1alpha induces fibrosis and insulin
resistance in white adipose tissue. Mol. Cell. Biol. 29, 4467–4483.
Hotamisligil, G.S., Shargill, N.S., and Spiegelman, B.M. (1993). Adipose
expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin
resistance. Science 259, 87–91.
Inouye, K.E., Shi, H., Howard, J.K., Daly, C.H., Lord, G.M., Rollins, B.J., and
Flier, J.S. (2007). Absence of CC chemokine ligand 2 does not limit obesity-
associated infiltration of macrophages into adipose tissue. Diabetes 56,
2242–2250.
Jostock, T., Mu¨llberg, J., Ozbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M.,
Neurath, M.F., and Rose-John, S. (2001). Soluble gp130 is the natural inhibitor
of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem.
268, 160–167.
Kado, S., Nagase, T., and Nagata, N. (1999). Circulating levels of interleukin-6,
its soluble receptor and interleukin-6/interleukin-6 receptor complexes in
patients with type 2 diabetes mellitus. Acta Diabetol. 36, 67–72.
Kamei, N., Tobe, K., Suzuki, R., Ohsugi, M., Watanabe, T., Kubota, N.,
Ohtsuka-Kowatari, N., Kumagai, K., Sakamoto, K., Kobayashi, M., et al.
(2006). Overexpression of monocyte chemoattractant protein-1 in adipose tis-
sues causes macrophage recruitment and insulin resistance. J. Biol. Chem.
281, 26602–26614.
Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., Kitazawa,
S., Miyachi, H., Maeda, S., Egashira, K., and Kasuga, M. (2006). MCP-1 con-
tributes to macrophage infiltration into adipose tissue, insulin resistance, and
hepatic steatosis in obesity. J. Clin. Invest. 116, 1494–1505.
Kim, J.Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M.E., Hofmann,
S.M., Schraw, T., Durand, J.L., Li, H., Li, G., et al. (2007). Obesity-associated
improvements in metabolic profile through expansion of adipose tissue.
J. Clin. Invest. 117, 2621–2637.CeKirk, E.A., Sagawa, Z.K., McDonald, T.O., O’Brien, K.D., and Heinecke, J.W.
(2008). Monocyte chemoattractant protein deficiency fails to restrain macro-
phage infiltration into adipose tissue [corrected]. Diabetes 57, 1254–1261.
Kraakman,M.J., Allen, T.L., Whitham,M., Iliades, P., Kammoun, H.L., Estevez,
E., Lancaster, G.I., and Febbraio, M.A. (2013). Targeting gp130 to prevent
inflammation and promote insulin action. Diabetes Obes. Metab. 15 (3),
170–175.
Kulkarni, O., Pawar, R.D., Purschke, W., Eulberg, D., Selve, N., Buchner, K.,
Ninichuk, V., Segerer, S., Vielhauer, V., Klussmann, S., and Anders, H.J.
(2007). Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in
MRL-(Fas)lpr mice. J. Am. Soc. Nephrol. 18, 2350–2358.
Lazar, M.A. (2005). How obesity causes diabetes: not a tall tale. Science 307,
373–375.
Mathis, D. (2013). Immunological goings-on in visceral adipose tissue. Cell
Metab. 17, 851–859.
Matthews, V., Schuster, B., Schu¨tze, S., Bussmeyer, I., Ludwig, A.,
Hundhausen, C., Sadowski, T., Saftig, P., Hartmann, D., Kallen, K.J., and
Rose-John, S. (2003). Cellular cholesterol depletion triggers shedding of
the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol.
Chem. 278, 38829–38839.
Matthews, V.B., Allen, T.L., Risis, S., Chan, M.H., Henstridge, D.C., Watson,
N., Zaffino, L.A., Babb, J.R., Boon, J., Meikle, P.J., et al. (2010). Interleukin-
6-deficient mice develop hepatic inflammation and systemic insulin resis-
tance. Diabetologia 53, 2431–2441.
Mauer, J., Chaurasia, B., Goldau, J., Vogt, M.C., Ruud, J., Nguyen, K.D.,
Theurich, S., Hausen, A.C., Schmitz, J., Bro¨nneke, H.S., et al. (2014).
Signaling by IL-6 promotes alternative activation of macrophages to limit
endotoxemia and obesity-associated resistance to insulin. Nat. Immunol. 15,
423–430.
Naugler, W.E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A.M., and
Karin, M. (2007). Gender disparity in liver cancer due to sex differences in
MyD88-dependent IL-6 production. Science 317, 121–124.
Nicholls, H.T., Kowalski, G., Kennedy, D.J., Risis, S., Zaffino, L.A., Watson, N.,
Kanellakis, P., Watt, M.J., Bobik, A., Bonen, A., et al. (2011). Hematopoietic
cell-restricted deletion of CD36 reduces high-fat diet-induced macrophage
infiltration and improves insulin signaling in adipose tissue. Diabetes 60,
1100–1110.
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano,
S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005). Humanized
anti-interleukin-6 receptor antibody treatment of multicentric Castleman
disease. Blood 106, 2627–2632.
Nishimura, S., Manabe, I., Nagasaki, M., Eto, K., Yamashita, H., Ohsugi, M.,
Otsu, M., Hara, K., Ueki, K., Sugiura, S., et al. (2009). CD8+ effector T cells
contribute to macrophage recruitment and adipose tissue inflammation in
obesity. Nat. Med. 15, 914–920.
Patsouris, D., Li, P.P., Thapar, D., Chapman, J., Olefsky, J.M., and Neels, J.G.
(2008). Ablation of CD11c-positive cells normalizes insulin sensitivity in obese
insulin resistant animals. Cell Metab. 8, 301–309.
Rabe, B., Chalaris, A., May, U., Waetzig, G.H., Seegert, D., Williams, A.S.,
Jones, S.A., Rose-John, S., and Scheller, J. (2008). Transgenic blockade of
interleukin 6 transsignaling abrogates inflammation. Blood 111, 1021–1028.
Rose-John, S., Waetzig, G.H., Scheller, J., Gro¨tzinger, J., and Seegert, D.
(2007). The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
Expert Opin. Ther. Targets 11, 613–624.
Sabio, G., Das, M., Mora, A., Zhang, Z., Jun, J.Y., Ko, H.J., Barrett, T., Kim,
J.K., and Davis, R.J. (2008). A stress signaling pathway in adipose tissue
regulates hepatic insulin resistance. Science 322, 1539–1543.
Schuett, H., Oestreich, R., Waetzig, G.H., Annema,W., Luchtefeld, M., Hillmer,
A., Bavendiek, U., von Felden, J., Divchev, D., Kempf, T., et al. (2012).
Transsignaling of interleukin-6 crucially contributes to atherosclerosis in
mice. Arterioscler. Thromb. Vasc. Biol. 32, 281–290.
Smolen, J.S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J.,
Alecock, E., Woodworth, T., and Alten, R.; OPTION Investigators (2008). Effect
of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoidll Metabolism 21, 403–416, March 3, 2015 ª2015 Elsevier Inc. 415
arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
Lancet 371, 987–997.
Talukdar, S., Oh, Y., Bandyopadhyay, G., Li, D., Xu, J., McNelis, J., Lu, M., Li,
P., Yan, Q., Zhu, Y., et al. (2012). Neutrophils mediate insulin resistance inmice
fed a high-fat diet through secreted elastase. Nat. Med. 18, 1407–1412.
Turner, N., Kowalski, G.M., Leslie, S.J., Risis, S., Yang, C., Lee-Young, R.S.,
Babb, J.R., Meikle, P.J., Lancaster, G.I., Henstridge, D.C., et al. (2013).
Distinct patterns of tissue-specific lipid accumulation during the induction of
insulin resistance in mice by high-fat feeding. Diabetologia 56, 1638–1648.
Wallenius, V., Wallenius, K., Ahre´n, B., Rudling, M., Carlsten, H., Dickson, S.L.,
Ohlsson, C., and Jansson, J.O. (2002). Interleukin-6-deficient mice develop
mature-onset obesity. Nat. Med. 8, 75–79.
Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and
Ferrante, A.W., Jr. (2003). Obesity is associated with macrophage accumula-
tion in adipose tissue. J. Clin. Invest. 112, 1796–1808.416 Cell Metabolism 21, 403–416, March 3, 2015 ª2015 Elsevier Inc.Wellen, K.E., and Hotamisligil, G.S. (2003). Obesity-induced inflammatory
changes in adipose tissue. J. Clin. Invest. 112, 1785–1788.
Wu, D., Molofsky, A.B., Liang, H.E., Ricardo-Gonzalez, R.R., Jouihan, H.A.,
Bando, J.K., Chawla, A., and Locksley, R.M. (2011). Eosinophils sustain adi-
pose alternatively activatedmacrophages associated with glucose homeosta-
sis. Science 332, 243–247.
Wunderlich, F.T., Stro¨hle, P., Ko¨nner, A.C., Gruber, S., Tovar, S., Bro¨nneke,
H.S., Juntti-Berggren, L., Li, L.S., van Rooijen, N., Libert, C., et al. (2010).
Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflam-
mation and improves systemic insulin action. Cell Metab. 12, 237–249.
Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols,
A., Ross, J.S., Tartaglia, L.A., and Chen, H. (2003). Chronic inflammation in fat
plays a crucial role in the development of obesity-related insulin resistance.
J. Clin. Invest. 112, 1821–1830.
